These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 29413505)

  • 21. Brain-derived neurotrophic factor, a new soluble biomarker for malignant pleural mesothelioma involved in angiogenesis.
    Smeele P; d'Almeida SM; Meiller C; Chéné AL; Liddell C; Cellerin L; Montagne F; Deshayes S; Benziane S; Copin MC; Hofman P; Le Pimpec-Barthes F; Porte H; Scherpereel A; Grégoire M; Jean D; Blanquart C
    Mol Cancer; 2018 Oct; 17(1):148. PubMed ID: 30309369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Updates in the diagnosis and treatment of malignant pleural mesothelioma.
    Katzman D; Sterman DH
    Curr Opin Pulm Med; 2018 Jul; 24(4):319-326. PubMed ID: 29553973
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential expression of extracellular matrix constituents and cell adhesion molecules between malignant pleural mesothelioma and mesothelial hyperplasia.
    Alì G; Borrelli N; Riccardo G; Proietti A; Pelliccioni S; Niccoli C; Boldrini L; Lucchi M; Mussi A; Fontanini G
    J Thorac Oncol; 2013 Nov; 8(11):1389-95. PubMed ID: 24084442
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relation between neutrophil/lymphocyte ratio and primary tumor metabolic activity in patients with malign pleural mesothelioma.
    Özyürek BA; Özmen Ö; Özdemirel TŞ; Erdoğan Y; Kaplan B; Kaplan T
    Clin Respir J; 2018 Feb; 12(2):646-651. PubMed ID: 27768834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of pregnancy-associated plasma protein A as a migration-promoting gene in malignant pleural mesothelioma cells: a potential therapeutic target.
    Huang J; Tabata S; Kakiuchi S; The Van T; Goto H; Hanibuchi M; Nishioka Y
    Oncotarget; 2013 Aug; 4(8):1172-84. PubMed ID: 23896451
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
    Guarrera S; Viberti C; Cugliari G; Allione A; Casalone E; Betti M; Ferrante D; Aspesi A; Casadio C; Grosso F; Libener R; Piccolini E; Mirabelli D; Dianzani I; Magnani C; Matullo G
    J Thorac Oncol; 2019 Mar; 14(3):527-539. PubMed ID: 30408567
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FDG PET/CT is useful for detecting infiltration to the port site in patients with malignant pleural mesothelioma.
    Kawaguchi K; Taniguchi T; Usami N; Fukui T; Ishiguro F; Nakamura S; Yokoi K
    Gen Thorac Cardiovasc Surg; 2014 Mar; 62(3):157-62. PubMed ID: 24281913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Malignant Pleural Mesothelioma: Accuracy of CT Against Immunohistochemical Test Among the Mexican Population.
    Gopar-Nieto R; Aguilar-Madrid G; Sotelo-Martínez L; Juárez-Pérez CA; Kelly-García J; Argote-Greene L; Ochoa-Vázquez MD; García-Bazán EM; Ramírez-Pérez J; Haro-García L; Jiménez-Ramírez C; Cabello-López A
    Arch Med Res; 2015 Feb; 46(2):107-11. PubMed ID: 25707292
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Considerations for Imaging of Malignant Pleural Mesothelioma: A Consensus Statement from the International Mesothelioma Interest Group.
    Katz SI; Straus CM; Roshkovan L; Blyth KG; Frauenfelder T; Gill RR; Lalezari F; Erasmus J; Nowak AK; Gerbaudo VH; Francis RJ; Armato SG
    J Thorac Oncol; 2023 Mar; 18(3):278-298. PubMed ID: 36549385
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical utility of 18F-FDG positron emission tomography in malignant peritoneal mesothelioma.
    Domènech-Vilardell A; Rasiej MJ; Taub RN; Ichise M
    Q J Nucl Med Mol Imaging; 2016 Mar; 60(1):54-61. PubMed ID: 24727854
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antagonizing the Hedgehog Pathway with Vismodegib Impairs Malignant Pleural Mesothelioma Growth In Vivo by Affecting Stroma.
    Meerang M; Bérard K; Felley-Bosco E; Lauk O; Vrugt B; Boss A; Kenkel D; Broggini-Tenzer A; Stahel RA; Arni S; Weder W; Opitz I
    Mol Cancer Ther; 2016 May; 15(5):1095-105. PubMed ID: 26839306
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New therapeutic strategies for malignant pleural mesothelioma.
    Bonelli MA; Fumarola C; La Monica S; Alfieri R
    Biochem Pharmacol; 2017 Jan; 123():8-18. PubMed ID: 27431778
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Molecular heterogeneity of malignant pleural mesotheliomas].
    Tranchant R; Montagne F; Jaurand MC; Jean D
    Bull Cancer; 2018 Jan; 105(1):35-45. PubMed ID: 29277245
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of imaging in the management of malignant pleural mesothelioma.
    Benamore RE; O'Doherty MJ; Entwisle JJ
    Clin Radiol; 2005 Dec; 60(12):1237-47. PubMed ID: 16291305
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of several biomarkers for the patients with malignant pleural mesothelioma.
    Liu H; Wu L; Ji K; Wang W
    Tumour Biol; 2015 Sep; 36(10):7375-84. PubMed ID: 26361957
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    Elliott HS; Metser U; de Perrot M; Cho J; Bradbury P; Veit-Haibach P; Hussey D; Noam T
    Br J Radiol; 2018 Jun; 91(1086):20170814. PubMed ID: 29498536
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Malignant pleural mesothelioma: single-institution experience of 101 patients over a 15-year period.
    Domen A; De Laet C; Vanderbruggen W; Gielis J; Hendriks JM; Lauwers P; Janssens A; Hiddinga B; Van Meerbeeck JP; Van Schil PE
    Acta Chir Belg; 2017 Jun; 117(3):157-163. PubMed ID: 28399779
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FDG PET-derived parameters as prognostic tool in progressive malignant pleural mesothelioma treated patients.
    Incerti E; Broggi S; Fodor A; Cuzzocrea M; Samanes Gajate AM; Mapelli P; Fiorino C; Dell'Oca I; Pasetti M; Cattaneo M; Calandrino R; Gianolli L; Di Muzio N; Picchio M
    Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2071-2078. PubMed ID: 29876617
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 18F-FDG Uptake of Localized Malignant Peritoneal Mesothelioma.
    Kodama E; Kodama T; Ichikawa T; Ikoma H; Hashimoto J
    Clin Nucl Med; 2020 Feb; 45(2):161-163. PubMed ID: 31876833
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BAP1 protein is a progression factor in malignant pleural mesothelioma.
    Arzt L; Quehenberger F; Halbwedl I; Mairinger T; Popper HH
    Pathol Oncol Res; 2014 Jan; 20(1):145-51. PubMed ID: 23963927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.